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Objective. We evaluated baseline data from the PApilloma TRIal against Cancer In young Adults (PATRICIA; NCT00122681)
on the association between behavioral risk factors and HPV infection and cervical abnormalities.
Methods. Women completed behavioral questionnaires at baseline. Prevalence of HPV infection and cervical abnormalities
(detected by cytological or histological procedures) and association with behavioral risk factors were analyzed by univariate
and stepwise multivariable logistic regressions., Av Fleming 20, 1330 Wavre, Belgium. Fax: +32 10 85 33 61.
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Results. 16782 women completed questionnaires. Among 16748 women with data for HPV infection,
4059 (24.2%) were infected with any HPV type. Among 16757 women with data for cytological abnormalities,
1626 (9.7%) had a cytological abnormality, of whom 1170 (72.0%) were infected with at least one oncogenic
HPV type including HPV-16 (22.7%) and HPV-18 (9.3%). Multivariable analysis (adjusted for age and region,
N=14404) showed a signiﬁcant association between infection with any HPV type and not living with a part-
ner, smoking, age b15 years at ﬁrst sexual intercourse, higher number of sexual partners during the past
12 months, longer duration of hormonal contraception and history of sexually transmitted infection (STI).
For cervical abnormalities, only history of STI (excluding Chlamydia trachomatis) remained signiﬁcant in
the multivariable analysis after adjusting for HPV infection.
Conclusions. Women reporting 3+ sexual partners in the past 12 months had the highest risk of HPV in-
fection at baseline. HPV infection was the main risk factor for cervical abnormalities, and history of STIs ex-
cluding Chlamydia trachomatis increased risk to a lesser extent. Although behavioral factors can inﬂuence
risk, all sexually active women are susceptible to HPV infection.© 2012 Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Human papillomavirus (HPV) is the causal agent in virtually all cer-
vical pre-cancer and cancer [1]. Currently, 13 HPV types are believed to
be carcinogenic [2], of which types HPV-16 and HPV-18 cause approxi-
mately 70% of cervical cancer [3]. Human papillomavirus is the most
common sexually transmitted infection (STI), although most infections
and low grade lesions clear spontaneously within 2 years [4–6].
Factors affecting viral persistence and lesion development are not
well understood [7]. Many studies have investigated the inﬂuence of
behavioral factors on acquisition and persistence of infection and de-
velopment of lesions [8–15], as well as the inﬂuence of immunosup-
pression and other infections such as Chlamydia trachomatis and
Herpes simplex virus [16–18]. Although there is some evidence that
these factors have an effect, associations are variable and often weak.
The PApilloma TRIal against Cancer In young Adults (PATRICIA) is a
phase III efﬁcacy study of the HPV-16/18 AS04-adjuvanted vaccine in
over 18000 youngwomen [19–21]. In addition to their primary objective
of demonstrating vaccine efﬁcacy, large trials such as PATRICIA can pro-
vide epidemiologic and behavioral information about populations and
natural history of disease. We collected baseline data from PATRICIA on
the prevalence of HPV infections and cervical abnormalities prior to vac-
cination and evaluated the association between potential behavioral risk
factors and HPV infection and/or cervical abnormalities at baseline.
Methods
The PATRICIA trial has been described previously [19,20]. The objec-
tives of the present analysis were to (1) describe the prevalence of be-
havioral risk factors, HPV infection, cytological abnormalities, and
cervical intraepithelial neoplasia (CIN); (2) assess the association be-
tween behavioral risk factors and presence of HPV infection, cytological
abnormalities, and CIN.
Participants and study procedures at baseline
This was a phase III, double-blind, randomized, multinational trial
(NCT00122681). Participants were healthy women aged 15–25 years,
enrolled irrespective of their HPV DNA status, HPV serostatus or cytolo-
gy at baseline. Written informed consent and/or assent was obtained
from all participants or their parents, and the trial was approved by in-
dependent ethics committees and institutional review boards.
Cervical liquid-based cytology samples were gathered and HPV
DNA detection and genotyping plus cytopathological examination
using the Bethesda system was performed. Cervical samples and
biopsy material were tested by PCR for DNA from 14 oncogenic HPV
types and 11 non-oncogenic types [22]. Cervical abnormalities evalu-
ated included any cytological abnormalities or histopathologically
conﬁrmed CIN. The same case deﬁnitions for cytological abnormali-
ties and CIN were used as for the efﬁcacy analyses [19,20].The mandatory behavioral questionnaire was a protocol-speciﬁed
study instrument (Table 1), self-administered (except in Brazil, where
it was administered by an investigator) at the second study visit.
Statistical analysis
The analysis of the behavioral questionnaire was performed for
the Total Vaccinated Cohort for the Behavioral Questionnaire
(TVC-BQ), and included all women who received at least one dose
of vaccine and completed the baseline questionnaire (Fig. 1).
The number and proportion of women with prevalent HPV infec-
tion and cervical abnormalities at baseline were computed with 95%
conﬁdence intervals (CI). The association between risk factors and
HPV infection or cervical abnormalities was analyzed by frequency
distributions, univariate logistic regressions and stepwise multivari-
able logistic regressions. Risk factors were retained for the multivari-
able analysis on the basis of their statistical signiﬁcance in the model
(pb0.05) and clinical relevance. Potential interactions between risk
factors were explored. Odds ratios (OR) for risk factors and associated
95% CI were computed without and with adjustment for age and geo-
graphical region. Analyses were stratiﬁed by age and region (Table 1).
Finland was treated separately from the rest of Europe because the
Finnish sites primarily recruited participants through schools and
thus had a relatively high proportion of younger participants [23].
The analysis of risk factors associated with cervical abnormalities
was also adjusted for prevalent HPV infections.
Women were excluded from the risk factor analysis if they had
missing data for HPV infection or if they stated that they had never
had sexual intercourse. The lifetime number of sexual partners was
not available because the questionnaire asked about the number of
sexual partners (1) during the past 12 months and (2) prior to the
past 12 months. For analysis of HPV infection, the number of sexual
partners during the past 12 months was used in the model, whereas
for cervical abnormalities, the number of sexual partners prior to
the past 12 months was used because of time needed to develop an
abnormality.
The risk factors included in the model are described in Table 1. Sev-
eral risk factors were not retained in the multivariable analysis due to
overlap or correlation with other risk factors. Cigarette smoking history
and cigarette smoking (number of packs per day) overlapped and
therefore only the latter was considered. At least one pregnancy and
at least one delivery were combined under a separate variable of preg-
nancy which included no pregnancy, abortion and delivery separately.
Duration of exposure was not retained because it was related to age at
ﬁrst sexual intercourse. The use of an intrauterine device (IUD) was
strongly correlated with at least one delivery, and therefore was not
retained for analysis of HPV infection. However, it was retained for anal-
ysis of cervical abnormalities because of its potential impact on the cer-
vix. Condom use was stratiﬁed by the number of partners; because
number of partners was also considered as an independent risk factor,
able 1
requency distribution at study entry of age group, region and risk factors considered
the behavioural questionnaire (TVC-BQ).
Risk factor Categories Frequency distribution
at study entry, n (%)
N=16782
Age group 15–17 years 5682 (33.9)
18–21 years 5116 (30.5)
22–25+years 5984 (35.7)
Regiona Asia Paciﬁc 5351 (31.9)
North America 2680 (16.0)
Latin America 2543 (15.2)
Finland 4681 (27.9)
Rest of Europe 1527 (9.1)
Marital status Married/living with partner 4841 (28.8)
Divorced/widowed 168 (1.0)
Single 11773 (70.2)
Education (number of
years education
completed)
b10 3247 (19.3)
10–14 10261 (61.1)
≥15 3274 (19.5)
Cigarette smoking
history
Never 10406 (62.0)
Former 2257 (13.4)
Current 4119 (24.5)
Cigarette smoking
(number of packs per
day)b
Never smoked 10406 (62.0)
b1 pack/day for b6 months 1385 (8.3)
b1 pack/day for ≥6 months or
≥1 pack/day for b6 months
4723 (28.1)
≥1 pack/day for ≥6 months 268 (1.6)
Age at ﬁrst sexual
intercoursec
Never had sexual intercourse 2348 (14.0)
b15 years 2083 (12.4)
15–18 years 9548 (56.9)
19–22 years 2584 (15.4)
23–25 years 219 (1.3)
Number of sexual
partners during the
past 12 monthsc,d
Never had sexual intercourse 2348 (14.0)
0 120 (0.7)
1 10909 (65.0)
2–3 2904 (17.3)
≥4 501 (3.0)
Number of sexual
partners prior to the
past 12 monthsc,d
Never had sexual intercourse 2348 (14.0)
0 1955 (11.6)
1 7414 (44.2)
2–3 3586 (21.4)
≥4 1479 (8.8)
Duration of sexual
exposurec,e
Never had sexual intercourse 2348 (14.0)
b1 year 1090 (6.5)
1–5 years 10002 (59.6)
6–10 years 2987 (17.8)
>10 years 355 (2.1)
Condom use according
to number of sexual
partners during the
past 12 monthsc,d
Never had sexual intercourse 2348 (14.0)
No partner 120 (0.7)
Never (≥2 partners) 2353 (14.0)
Never (b2 partners) 6662 (39.7)
Rarely/sometimes (≥2
partners)
174 (1.0)
Rarely/sometimes (b2
partners)
1670 (10.0)
Most/every time (≥2
partners)
878 (5.2)
Most/every time (b2 partners) 2577 (15.4)
Condom use according
to number of sexual
partners prior to the
past 12 monthsc,d
Never had sexual intercourse 2348 (14.0)
No partner 1955 (11.6)
Never (≥2 partners) 3605 (21.5)
Never (b2 partners) 4839 (28.8)
Rarely/sometimes (≥2
partners)
215 (1.3)
Rarely/sometimes (b2
partners)
1073 (6.4)
Most/every time (≥2 partners) 1245 (7.4)
Most/every time (b2 partners) 1502 (9.0)
Duration of hormonal
contraception
Never 6679 (39.8)
1–12 months 4984 (29.7)
13–48 months 3873 (23.1)
≥49 months 1246 (7.4)
Use of copper IUD Yes 863 (5.1)
No 15919 (94.9)
At least one pregnancy Yes 4888 (29.1)
No 11894 (70.9)
Table 1 (continued)
Risk factor Categories Frequency distribution
at study entry, n (%)
N=16782
At least one delivery Yes 3291 (19.6)
No 13491 (80.4)
Pregnancyf No 11894 (70.9)
Abortion 1597 (9.5)
Delivery 3291 (19.6)
STI history No 15843 (94.4)
Yes — Chlamydia trachomatis 345 (2.1)
Yes — other 594 (3.5)
a Rest of Europe: Belgium, Germany, Italy, Spain, UK; Asia Paciﬁc: Australia, Philippines,
Taiwan, Thailand; Latin America: Brazil, Mexico; North America: Canada, USA.
b Includes both current and past smoking.
c The interviewer informed participants that, for the purpose of the questionnaire, sex-
ual intercourse refers to penetrative, genital‐to‐genital, or oral‐to‐genital sexual contact.
d For analysis of HPV infection, the number of sexual partners during the past
12 months was considered; for analysis of cervical abnormalities, the number of sexual
partners prior to the past 12 months was considered.
e The duration of sexual exposure was computed as: date of behavioral questionnaire
minus date of ﬁrst sexual intercourse. The date of the behavioral questionnaire is the
date of completion of the questionnaire. The date ofﬁrst sexual intercoursewas computed
as: date of birth plus age at ﬁrst sexual intercourse.
f Women with both an abortion and a delivery were counted as a delivery.
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F
inboth risk factors could not be retained in the same stepwise multivari-
able analysis. In addition, a confusion effect with STI was suspected.
Condom use was therefore not retained.
Results
A total of 18644 women were included in the TVC, of whom 1862
were excluded from the TVC-BQ because of no data or obvious dis-
crepancies in the questionnaires following a consistency check by
the study statistician. Thus 16782 women were included in the
TVC-BQ (Fig. 1). Most participants were based in Asia Paciﬁc and Fin-
land; there was a similar number of women in each age stratum
(Table 1). The number of women with each behavioral risk factor is
shown in Table 1.
Prevalent HPV infections and cervical abnormalities at study entry
Of the 16748 women with data for HPV infection, 4059 (24.2%)
were infected with any HPV type at study entry, mainly HPV-16 and
HPV-18 (Table 2). The distribution of prevalent HPV infections by re-
gion is shown in Table S1. HPV infection was most common in partic-
ipants aged 16 or 17 years (Fig. 2). Of the 16757 women with data for
cervical abnormalities, 1627 (9.7%) had any cervical abnormality
detected by cytological or histological procedures (Table 2).
Occurrence of cervical abnormalities concomitant with prevalent HPV
infection at study entry
Among the 15155 women with normal cytology, 2254 (14.9%)
were infected with an oncogenic HPV type (Fig. 3). Among the 1626
women who had any cytological abnormality, 1170 (72.0%) were
infected with an oncogenic HPV type; a similar pattern was seen
with high grade cervical squamous intraepithelial lesion (HSIL) and
atypical squamous cells of undetermined signiﬁcance (ASC-US)
(Fig. 3). The distribution of individual HPV types is shown in Table S2.
Risk factor analysis — any HPV infection
A total of 14404 women were included in the analyses (Fig. 1), of
whom 4018 had an HPV infection. Based on the univariate analysis
and clinical relevance, the risk factors retained into the multivariable
analysis were marital status, number of cigarette packs smoked per
Number of subjects enrolled
N = 18729
TVC
N = 18644
TVC-BQ
N = 16782
Number of subjects excluded from TVC
N = 85
21 concerns about data integrity
64 study vaccine not administered
Number of subjects excluded from TVC-BQb
N = 1862 (332 no questionnaire data 
available; 1530 discrepancies in answers)
Main discrepancies: multiple responses to 
the same question, inconsistencies between 
answers to related questions, anomalies 
between past and current smoking habits, 
and missing datac
Subjects with available 
data for HPV infection
N = 16748
Subjects with available data 
for cervical abnormalities
N = 16757
TVC-BQ for univariateand multivariable 
logistic regressions
N = 14404 (except for condom usea)
Number of subjects excluded from logistic 
regression analyses
N = 2378
2348 subjects who stated they had never 
had sexual intercourse were excluded (2303 
[98.08%] with no HPV infection, 41 [1.75%] 
with HPV infection, 4 [0.17%] with missing 
data)
30 subjects with experience of sexual 
intercourse and missing data for HPV 
infection were excluded
Fig. 1. Subject disposition. aWomen who stated that they were previously sexually active but had had no sexual partner during the past 12 months were excluded from the univariate
analysis of condom use and HPV infection (N=14284). Women who stated that they were previously sexually active but had had no sexual partner prior to the past 12 months were
excluded from the univariate analysis of condom use and cervical abnormalities (N=12452). bThere were some demographic differences between the women who were excluded
and the TVC‐BQ, with a higher proportion of women aged 22–25+ years and women from Asia Paciﬁc being excluded. Of the women excluded, 13.0% were aged 15–17 years, 34.6%
were aged 18–21 years and 52.4% were aged 22–25+ years, whilst 53.8% were from Asia Paciﬁc, 21.1% from North America, 12.4% from Latin America, 6.8% from Finland and 5.9%
from rest of Europe. cQuestionnaires with major discrepancies were excluded from the analysis (N=1530). If only minor discrepancies were identiﬁed, the inconsistency was corrected
or recorded as a missing value and included in the analysis if the variable was included in the analysis. If the variable was not included in the analysis, it was not corrected.
443E. Roset Bahmanyar et al. / Gynecologic Oncology 127 (2012) 440–450day, age at ﬁrst sexual intercourse, number of sexual partners during
the past 12 months, duration of hormonal contraception, pregnancy,
and STI history (Table 3).
The multivariable analysis (adjusted for age and region) showed a
signiﬁcant association between infection with any HPV type and not
being married or living with a partner, higher number of cigarette
packs smoked per day, age b15 years at ﬁrst sexual intercourse,
higher number of sexual partners during the past 12 months, longer
duration of hormonal contraceptive use, and history of STI
(Table 3). Where risk factors were analyzed for different levels of
risk, the OR demonstrated a gradient with the level of exposure. The
OR for pregnancies resulting in delivery suggested a protective effect
against HPV infection. A relatively high proportion of women were
infected with HPV even in the lowest risk group for each risk factor
in the analysis (at least 14.5%) (Table 3).
Compared with women who never used condoms and had ≥2
partners (reference category), condom use in the univariate analysis
was signiﬁcantly protective for women who used a condom and had
≥2 partners during the past 12 months; women who never used a
condom and had b2 partners also had a signiﬁcant risk reduction.
However, the risk increased among condom users who had b2
partners.
The risk of HPV infection did not signiﬁcantly change by year of age
(OR=1.01 [0.99, 1.03]). Women in Latin America and North America
were more likely to have an HPV infection than women living in rest
of Europe (the reference category) (Table 3).
Risk factor analysis — any cervical abnormality (cytological
abnormalities and histopathologically conﬁrmed CIN)
A total of 14404 women were included in the analyses (Fig. 1), of
whom 1592 had a cervical abnormality. Risk factors were included in
the multivariable analysis if they were suspected to have an inherentimpact on the cervix and were signiﬁcant in the univariate analysis:
number of cigarette packs smoked per day, age atﬁrst sexual intercourse,
duration of hormonal contraception, use of IUD, pregnancy, and STI
history. Condom use and duration of exposure were not retained in the
multivariable analysis for the same reasons as described earlier. A combi-
nation of risk factors for cigarette smoking and pregnancy was used as
described previously.
The multivariable analysis indicated an increased risk of cervical ab-
normalities for the number of cigarette packs smoked per day (b1 pack/
day for ≥6 months/≥1 pack/day for b6 months and ≥1 pack/day for
≥6 months), b15 years at ﬁrst sexual intercourse, duration of hormon-
al contraception (1–12 and 13–48 months), and STI history (Table 3).
An OR of 0.75 (95% CI: 0.63, 0.89) for pregnancies resulting in delivery
indicated a protective effect (Table 3).When the analysis of any cervical
abnormality was adjusted for HPV infection, only history of an STI other
than Chlamydia trachomatis remained signiﬁcant (Table 3).
There was no signiﬁcant association of age as a continuous variable
with any cervical abnormality (Table 3). Women in Latin America and
North America were more likely, and women in Asia-Paciﬁc less likely,
to have a cervical abnormality than women living in the rest of Europe;
however, this did not remain signiﬁcant when adjusted for HPV infec-
tion (Table 3).Discussion
Our analysis showed a signiﬁcant association between several be-
havioral risk factors (not married or living with a partner, smoking,
young age at ﬁrst sexual intercourse, higher number of sexual partners,
longer duration of hormonal contraceptive use, condomuse, and history
of STI) and infectionwith any HPV type. In the analysis of risk factors as-
sociated with any cervical abnormality, only STI history was associated
with a signiﬁcantly higher risk after adjustment for HPV infection.
Table 2
Prevalence of HPV infections or cervical abnormalities at study entry.
Womenwith infections or
cervical abnormalities
n % 95% CI
Data available for HPV infections (N=16748)
No HPV infection 12689 75.8 75.1, 76.4
Any HPV typea 4059 24.2 23.6, 24.9
Any oncogenic HPV typea 3425 20.5 19.8, 21.1
Any non-oncogenic HPV typea 1447 8.6 8.2, 9.1
Any multiple HPV typesa 1660 9.9 9.5, 10.4
Any oncogenic type excluding HPV-16 and HPV-18 2201 13.1 12.6, 13.7
HPV-16 931 5.6 5.2, 5.9
HPV-18 381 2.3 2.1, 2.5
HPV-16 and HPV-18 88 0.5 0.4, 0.6
HPV-31 393 2.3 2.1, 2.6
HPV-33 169 1.0 0.9, 1.2
HPV-45 143 0.9 0.7, 1.0
HPV-51 702 4.2 3.9, 4.5
Data available for cervical abnormalities (N=16757)
Normal cytology (no cytological abnormality and no CIN) 15130 90.3 89.8, 90.7
Any cervical abnormality (cytological abnormality or CIN) 1627 9.7 9.3, 10.2
Any cytological abnormalityb 1626 9.7 9.3, 10.2
ASC-US 773 4.6 4.3, 4.9
ASC-H 19 0.1 0.1, 0.2
LSIL 773 4.6 4.3, 4.9
HSIL 53 0.3 0.2, 0.4
AGC 8 0.0 0.0, 0.1
N=number of women with available data.
ForHPV infections,n=number ofwomenwith the speciﬁedHPV type (irrespective of the re-
sults for other HPV types, except for anymultiple infectionwhich excludes single infections).
For cervical abnormalities, n=number of women with the speciﬁed abnormality.
%=100*n/N.
95% CI=exact 95% two-sided conﬁdence interval for percentage.
a Oncogenic or non‐oncogenic: oncogenic HPV types were considered as HPV‐16, 18,
31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68; non‐oncogenic HPV types as HPV‐6, 11, 34,
40, 42, 43, 44, 53, 54, 70, 74.
b Cytological abnormalities included: atypical squamous cells of undetermined sig-
niﬁcance (ASC‐US), high‐grade squamous cell intraepithelial lesion (HSIL), atypical
squamous cells in which high‐grade squamous intraepithelial lesions could not be ex-
cluded (ASC‐H), low‐grade squamous cell intraepithelial lesion (LSIL), and atypical
glandular cells of undetermined signiﬁcance (AGC).
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paradoxical ﬁndings. Women who used condoms and had at least two
partners during the past 12 months had a lower risk of HPV infection
than the reference group (women who never used condoms and had
at least two partners during the past 12 months). Women who used
condoms and had fewer than two partners during the past 12 months
had an increased risk versus the reference group. History of Chlamydia
trachomatis infection was between two and four times as common in
women who used condoms most or all of the time and had fewer than
two partners during the past 12 months comparedwith all other groups
(data not shown). A paradoxical increase in HPV infection with condom
use has been previously reported, possibly because women may be
more likely to use a condom if they believe there is a high risk of STI
transmission from a partner [24].
Many studies evaluating the inﬂuence of risk factors on HPV infec-
tion or cervical abnormalities have produced conﬂicting results. In com-
mon with our ﬁndings, several studies have reported a signiﬁcant
association between recent smoking and HPV infection [25–28] and be-
tween smoking and HPV persistence [14]. Other studies have shown no
association [29–32]. As reported elsewhere [11,12,29,33–36], our study
found that smoking increased the risk of cervical abnormalities, al-
though the association disappeared when the analysis was adjusted
for HPV infection. One study found that young women who smoke
have an impaired antibody response to HPV-16 and HPV-18 compared
with non-smokers [37].We found that longer duration of hormonal contraception use was
associated with increased risk of HPV infection. Again, several studies
have reported conﬂicting results for this association [8,12–14,38,39],
although a systematic review has shown a consistent association be-
tween long-term hormonal contraception use in women infected
with oncogenic HPV types and development of cervical cancer or
CIN3 lesions [40]. A possible biological mechanism for the impact of
hormonal contraception is enhanced hydroxylation of estradiol to
16α-hydroxyestrone in cervical cells infected with some oncogenic
HPV types, which in turn induces increased transcription of the E6
and E7 HPV oncogenes [41].
Confounding is a problem in analyses of hormonal contraception
use and smoking because both are associated with other risk-taking
behaviors [42–44]. However, both factors were independently signif-
icant in our multivariable analysis, suggesting a true effect. Our anal-
ysis of condom use was confounded by history of STI, as discussed
earlier; other studies have produced conﬂicting results regarding
the possible inﬂuence of condom use on HPV infection [9,45]. As in
our study, the TOMBOLA study showed that childbirth and previous
pregnancy were associated with a lower risk of HPV infection [13].
Women who were not married or living with a partner had a
higher risk of HPV infection, as shown previously [46–48]. We also
showed an association with increasing number of sexual partners
during the past 12 months and HPV infection. An analysis of HPV in-
fection at baseline in studies of the HPV-6/11/16/18 vaccine also
showed a correlation between HPV infection and number of lifetime
sexual partners [49]. We also found a trend for a stronger association
between lower age at sexual debut and HPV infection, although this
was not controlled for the lifetime number of sexual partners. It has
been suggested that acquisition of HPV infection may be more likely
in adolescent women because the structural immaturity of the trans-
formation zone makes the epithelium more susceptible to viral entry
and persistence [50,51].
History of Chlamydia trachomatis infection and other STIs was signif-
icantly associated with HPV infection, as previously seen for Chlamydia
infection [52–54]. A possible association with other STIs is less clear
[reviewed in 55]. Chlamydia infection also increases the risk of persis-
tent HPV infection [56,57] and invasive cervical cancer [17,58]. Only his-
tory of STIs excluding Chlamydia remained signiﬁcantly associatedwith
cervical abnormalities after adjustment for HPV infection in our study,
although it should be noted that the OR was low and only marginally
signiﬁcant, and may be due to chance.
The PATRICIA study population included a diverse group of young
women, most of whom were already sexually active [20]. A relatively
large proportion had a prevalent HPV infection at study entry, although
less than 1% had an active infectionwith both HPV-16 andHPV-18. Sim-
ilar levels of infection at baseline were seen in studies of the HPV-6/11/
16/18 vaccine [49]. Among the 614 women who were in the lowest
category for all risk factors, 10% were infected with HPV (data not
shown). This illustrates that, although behavioral factors can inﬂuence
the risk of HPV infection, ‘low risk’ sexually active women may still
acquire the virus.
The highest prevalence of HPV infection was seen in participants
aged 16 and 17 years, in accordance with previous ﬁndings that
HPV infection often occurs shortly after sexual debut [59]. The high
prevalence in this age group may be explained by behavioral factors.
A larger proportion of women aged 15–17 years than 18–25 years
reported at least three sexual partners in the past 12 months and a
smaller proportion reported only one sexual partner, while a larger
proportion of women aged 18–25 years than 15–17 years reported
that they had never smoked or had smoked for ≤6 months (data
not shown). Most participants aged 16 and 17 years were recruited
from Finland, making it difﬁcult to understand whether the high
prevalence in this age group was particular to Finland or applied else-
where. Few participants aged 15 years were infected with HPV. This
suggests that vaccination at 15 years may be a reasonable alternative
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Fig. 2. Age distribution of HPV infection at study entry.
445E. Roset Bahmanyar et al. / Gynecologic Oncology 127 (2012) 440–450to vaccination at a younger age if necessary, although this may vary in
different geographic regions.
This analysis had several important strengths, including a large
sample from a broad population of womenwith up to six lifetime sex-
ual partners, with high quality data collected as part of a phase III
trial. The questionnaire was mainly self-administered, which has
been shown to be a reliable way of collecting information about
some sexual behaviors [60–62]. However, participants may not haveAny HPV type (oncogenic or non-oncogenic) Any o
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Fig. 3. Occurrence of cervical abnormalities concomitwished to disclose details concerning sexual behavior, and reporting
may therefore be biased.
Aweakness of the analyseswas that therewasnoopportunity to cor-
rect errors and inconsistencies in the responses. Therefore, some entire
questionnaires (when major inconsistencies were found) or individual
questions (minor inconsistencies) had to be eliminated. A weakness of
the questionnaire was the structure of the question about number of
partners, i.e., (1) during the past 12 months, or (2) prior to the pastncogenic HPV type Any non-oncogenic HPV type
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ant with prevalent HPV infection at study entry.
Table 3
Risk factors associated with HPV infection (any type) and any cervical abnormality (cytological abnormality or histopathologically conﬁrmed CIN) at study entry (logistic regression analyses).
Risk factor Category HPV infection Any cervical abnormality
n (%) Univariate analysis
adjusted by age and
region OR (95% CI)
Multivariable analysis
adjusted by age and
region OR (95% CI)
n (%) Univariate analysis
adjusted by age and
region OR (95% CI)
Multivariable analysis
adjusted by age and
region OR (95% CI)
Multivariable analysis
adjusted by age,
region and HPV
infection OR (95% CI)
Marital status Married/living with partner 979 (20.3) 1 1 350 (7.3) 1 NRMA NRMA
Divorced/widowed 59 (35.1) 1.91 (1.37, 2.65) 1.56 (1.10, 2.21) 21 (12.5) 1.65 (1.02, 2.64)
Single 2980 (31.6) 1.60 (1.45, 1.76) 1.36 (1.21, 1.52) 1221 (13.0) 1.42 (1.23, 1.63)
Education (number of years
education completed)
b10 681 (25.3) 1 NRMA 248 (9.2) 1 NRMA NRMA
10–14 2505 (28.7) 1.09 (0.99, 1.21) 1038 (11.9) 1.22 (1.05, 1.42)
≥15 832 (27.9) 1.15 (1.00, 1.31) 306 (10.3) 1.24 (1.02, 1.52)
Cigarette smoking
(number of packs per day)
Never smoked 2008 (23.7) 1 1 791 (9.4) 1 1 NRSS
b1 pack/day for b6 months 353 (29.0) 1.29 (1.12, 1.48) 1.21 (1.05, 1.39) 137 (11.2) 1.10 (0.91, 1.34) 1.10 (0.90, 1.34)
b1 pack/d for ≥6 m or ≥1 pack/d for b6 m 1546 (34.6) 1.67 (1.54, 1.82) 1.36 (1.24, 1.49) 619 (13.9) 1.37 (1.22, 1.54) 1.29 (1.14, 1.45)
≥1 pack/day for ≥6 months 111 (41.9) 2.09 (1.62, 2.70) 1.63 (1.25, 2.13) 45 (17.0) 1.80 (1.29, 2.52) 1.69 (1.20, 2.38)
Age at ﬁrst sexual intercourse 23–25 33 (15.1) 1 1 9 (16.0) 1 1 NRSS
19–22 515 (20.0) 1.28 (0.87, 1.89) 1.22 (0.82, 1.80) 203 (4.1) 1.73 (0.87, 3.44) 1.69 (0.85, 3.36)
15–18 2673 (28.1) 1.76 (1.20, 2.57) 1.49 (1.00, 2.20) 1047 (7.9) 1.86 (0.94, 3.67) 1.68 (0.85, 3.35)
b15 797 (38.3) 2.75 (1.85, 4.08) 1.88 (1.25, 2.84) 333 (11.0) 2.55 (1.28, 5.10) 2.04 (1.01, 4.14)
Number of sexual partnersa 0 21 (17.5) 1 1 161 (8.2) 1 NRMA NRMA
1 2442 (22.4) 1.36 (0.84, 2.19) 1.36 (0.84, 2.21) 570 (7.7) 1.23 (1.02, 1.49)
2–3 1239 (42.7) 3.50 (2.16, 5.66) 3.09 (1.90, 5.03) 583 (16.3) 2.49 (2.06, 3.02)
≥4 316 (63.1) 9.29 (5.57, 15.50) 7.62 (4.55, 12.79) 278 (18.8) 2.97 (2.39, 3.68)
Duration of sexual exposure b1 year 157 (14.5) 1 NRMA 82 (7.6) 1 NRMA NRMA
1–5 years 2851 (28.5) 2.56 (2.14, 3.06) 1167 (11.7) 1.85 (1.46, 2.34)
6–10 years 907 (30.5) 3.36 (2.73, 4.14) 296 (9.9) 2.01 (1.51, 2.68)
>10 years 103 (29.2) 3.00 (2.20, 4.08) 47 (13.3) 2.73 (1.80, 4.14)
Condom usea Never (≥2 partners) 1029 (43.8) 1 NRMA 621 (17.3) 1 NRMA NRMA
Never (b2 partners) 1431 (21.5) 0.34 (0.31, 0.38) 379 (7.8) 0.47 (0.41, 0.54)
Rarely/sometimes (b2 partners) 76 (43.7) 1.10 (0.80, 1.51) 34 (15.9) 1.35 (0.92, 1.99)
Rarely/sometimes (≥2 partners) 345 (20.8) 0.42 (0.36, 0.49) 57 (5.4) 0.45 (0.33, 0.61)
Most/every time (b2 partners) 450 (51.3) 1.34 (1.14, 1.57) 206 (16.6) 1.04 (0.88, 1.24)
Most/every time (≥2 partners) 666 (25.9) 0.43 (0.38, 0.49) 134 (8.9) 0.56 (0.46, 0.68)
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Risk factor
Category HPV infection Any cervical abnormality
n (%) Univariate analysis
adjusted by age and
region OR (95% CI)
Multivariable analysis
adjusted by age and
region OR (95% CI)
n (%) Univariate analysis
adjusted by age and
region OR (95% CI)
Multivariable analysis
adjusted by age and
region OR (95% CI)
Multivariable analysis
adjusted by age,
region and HPV
infection OR (95% CI)
Duration of hormonal contraception Never 1026 (22.1) 1 1 400 (8.6) 1 1 NRSS
1–12 months 1422 (30.0) 1.34 ( 1.22; 1.47) 1.35 (1.22, 1.49) 588 (12.4) 1.33 (1.16, 1.52) 1.27 (1.10, 1.46)
13–48 months 1118 (29.6) 1.28 (1.16, 1.42) 1.26 (1.13, 1.40) 457 (12.1) 1.29 (1.11, 1.49) 1.18 (1.01, 1.37)
≥49 months 452 (36.7) 1.80 (1.55, 2.09) 1.59 (1.36, 1.86) 147 (11.9) 1.37 (1.10, 1.70) 1.18 (0.94, 1.47)
Use of copper IUD No 3815 (28.2) 1 NRMA 1518 (11.2) 1 1 NRSS
Yes 203 (23.6) 0.59 (0.50, 0.71) 74 (8.6) 0.72 (0.55, 0.93) NRSS
Pregnancy No pregnancy 2849 (29.9) 1 1 1163 (12.2) 1 1 NRSS
Abortion 485 (30.5) 1.20 (1.06, 1.36) 1.06 (0.93, 1.21) 181 (11.4) 1.21 (1.01, 1.44) 1.01 (0.84, 1.21)
Delivery 684 (20.8) 0.70 (0.63, 0.78) 0.82 (0.72, 0.93) 248 (7.6) 0.82 (0.70, 0.97) 0.75 (0.63, 0.89)
STI history No 3533 (26.2) 1 1 1373 (10.2) 1 1 1
Yes — Chlamydia trachomatis 205 (59.4) 3.56 (2.85, 4.45) 2.84 (2.25, 3.58) 86 (24.9) 2.44 (1.89, 3.16) 2.21 (1.70, 2.87) 1.20 (0.90, 1.60)
Yes — other 280 (47.5) 2.24 (1.89, 2.66) 1.94 (1.63, 2.32) 133 (22.6) 2.34 (1.91, 2.88) 2.21 (1.79, 2.72) 1.57 (1.24, 1.99)
Age (years) Numerical/continuous variable 4018 (27.9) NR 1.01 (0.99, 1.03) 1592 (11.1) NR 0.97 (0.94, 1.00) 0.96 (0.93, 0.99)
Region Rest of Europe 409 (28.9) NR 1 159 (11.3) NR 1 1
Asia Paciﬁc 892 (18.5) NR 1.15 (0.98, 1.35) 301 (6.3) NR 0.76 (0.61, 0.95) 0.79 (0.63, 0.99)
North America 899 (37.2) NR 1.48 (1.27, 1.72) 371 (15.3) NR 1.38 (1.12, 1.70) 1.12 (0.90, 1.40)
Latin America 879 (36.9) NR 2.41 (2.06, 2.82) 303 (12.7) NR 1.45 (1.17, 1.80) 0.96 (0.77, 1.21)
Finland 939 (27.8) NR 0.85 (0.72, 1.01) 458 (13.6) NR 1.10 (0.87, 1.38) 1.13 (0.88, 1.46)
For HPV infection, N=14404 (4018 with HPV infection and 10386 without infection) for all univariate and multivariable analyses except the univariate analysis of condom use where N=14284 (3997 with HPV infection and 10287 without
infection; women who stated that they had previously been sexually active but had had no sexual partner during the past 12 months were excluded).
For cervical abnormalities, N=14404 (1592 with a cervical abnormality and 12812 with no abnormality) for all univariate and multivariable analyses except the univariate analysis of condom use where N=12452 (1431 with a cervical
abnormality and 11021 with no abnormality; women who stated that they had previously been sexually active but had had no sexual partner prior to the past 12 months were excluded).
OR=1 indicates reference category.
n (%): number and percentage of women in speciﬁed category with an HPV infection or cervical abnormality at study entry.
NR: Not reported (results are not reported here because they are different for each univariate analysis).
NRMA: Not retained into the multivariable analysis.
NRSS: Not retained by stepwise selection.
a Number of sexual partners during the past 12 months was used for the analysis of HPV infection, and number prior to the past 12 months for analysis of cervical abnormalities.
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448 E. Roset Bahmanyar et al. / Gynecologic Oncology 127 (2012) 440–45012 months. It was not possible to add the number of partners from the
two responses together to estimate the lifetime number of partners,
whichwould have allowed a better comparison of our results with pub-
lished literature.
In conclusion, a relatively large number of young women in this
diverse population was infected with oncogenic HPV types at study
entry, although only a small proportion was infected with both
HPV-16 and HPV-18. Risk factor analysis showed that behavioral fac-
tors can increase the risk of HPV infection, although even those sexu-
ally active women who were in low-risk categories were vulnerable.
Women with the highest risk of HPV infection were those who had
a high (3+) number of sexual partners in the past 12 months. HPV
infection was the main risk factor for development of a cervical ab-
normality. A history of STIs other than Chlamydia trachomatis also in-
creased the risk, but to a lesser extent. This study conﬁrms many of
the previously identiﬁed behavioral risk factors associated with HPV
infection, but in a population that is geographically diverse. This
study also conﬁrms that, despite behavioral risk factors, all sexually
active women are at risk of HPV infection and subsequent develop-
ment of a cervical abnormality.
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